Oppenheimer reiterated their Outperform rating and $7 price target Protalix BioTherapeutics (NYSE: PLX) after Uplys received approval from the Brazilian ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE